WO2000056922A3 - Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof - Google Patents

Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof Download PDF

Info

Publication number
WO2000056922A3
WO2000056922A3 PCT/GB2000/001102 GB0001102W WO0056922A3 WO 2000056922 A3 WO2000056922 A3 WO 2000056922A3 GB 0001102 W GB0001102 W GB 0001102W WO 0056922 A3 WO0056922 A3 WO 0056922A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease status
compositions
assessing disease
genetic polymorphism
polymorphic pattern
Prior art date
Application number
PCT/GB2000/001102
Other languages
French (fr)
Other versions
WO2000056922A2 (en
Inventor
Per Harry Rutger Lindstrom
Leif Torbjorn Norberg
Lena Jonsson
Erik Olaisson
Rhiannon Sanders
Original Assignee
Gemini Genomics Ab
Per Harry Rutger Lindstrom
Leif Torbjorn Norberg
Lena Jonsson
Erik Olaisson
Rhiannon Sanders
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemini Genomics Ab, Per Harry Rutger Lindstrom, Leif Torbjorn Norberg, Lena Jonsson, Erik Olaisson, Rhiannon Sanders filed Critical Gemini Genomics Ab
Priority to AU34422/00A priority Critical patent/AU3442200A/en
Publication of WO2000056922A2 publication Critical patent/WO2000056922A2/en
Publication of WO2000056922A3 publication Critical patent/WO2000056922A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The present invention provides methods for assessing disease status in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding a protein involved in a physiologic pathway associated with a treatment regime. The invention also provides isolated nucleic acids encoding. These polymorphisms, nucleic acid probes that hybridize to polymorphic positions, kits for the prediction of disease status, and nucleic acid and peptide targets for use in identifying candidate drugs.
PCT/GB2000/001102 1999-03-23 2000-03-23 Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof WO2000056922A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34422/00A AU3442200A (en) 1999-03-23 2000-03-23 Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12604699P 1999-03-23 1999-03-23
EPPCT/IB99/00497 1999-03-23
US60/126,046 1999-03-23
IB9900497 1999-03-23
US12624399P 1999-03-24 1999-03-24
US60/126,243 1999-03-24
US47189099A 1999-12-23 1999-12-23
US09/471,890 1999-12-23

Publications (2)

Publication Number Publication Date
WO2000056922A2 WO2000056922A2 (en) 2000-09-28
WO2000056922A3 true WO2000056922A3 (en) 2000-12-21

Family

ID=27383337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001102 WO2000056922A2 (en) 1999-03-23 2000-03-23 Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof

Country Status (2)

Country Link
AU (1) AU3442200A (en)
WO (1) WO2000056922A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733144C (en) 2003-12-17 2017-07-04 Fred Hutchinson Cancer Research Center Methods and materials for canine breed identification
WO2009113985A1 (en) * 2008-03-13 2009-09-17 Maria Athanasiou Genetic markers associated with response to antidepressants
US20100331673A1 (en) 2009-06-26 2010-12-30 Michael Maschke System and method for reducing patient risk of allergic reaction to contrast agents or medical material

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003633A1 (en) * 1992-07-31 1994-02-17 Garvan Institute Of Medical Research Assessment of trans-acting factors allelic variation
WO1996022387A1 (en) * 1995-01-16 1996-07-25 Garvan Institute Of Medical Research Diagnostic method using estrogen receptor gene polymorphisms
WO1998045477A2 (en) * 1997-04-04 1998-10-15 Eurona Medical Ab Methods for assessing cardiovascular status and compositions for use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003633A1 (en) * 1992-07-31 1994-02-17 Garvan Institute Of Medical Research Assessment of trans-acting factors allelic variation
WO1996022387A1 (en) * 1995-01-16 1996-07-25 Garvan Institute Of Medical Research Diagnostic method using estrogen receptor gene polymorphisms
WO1998045477A2 (en) * 1997-04-04 1998-10-15 Eurona Medical Ab Methods for assessing cardiovascular status and compositions for use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; HERRMANN S M ET AL: "Identification of two polymorphisms in the promoter of the microsomal triglyceride transfer protein ( MTP ) gene: lack of association with lipoprotein profiles.", XP002125520, retrieved from STN Database accession no. 1999051356 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; TAN S ET AL: "Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics [see comments].", XP002125521, retrieved from STN Database accession no. 97470098 *
JOURNAL OF LIPID RESEARCH, (1998 DEC) 39 (12) 2432-5. *
LANCET, (1997 OCT 4) 350 (9083) 995-9. *

Also Published As

Publication number Publication date
WO2000056922A2 (en) 2000-09-28
AU3442200A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
Casey et al. Mutations in the protein kinase A R1α regulatory subunit cause familial cardiac myxomas and Carney complex
WO2003012046A3 (en) Stk15 (stk6) gene polymorphism and methods of determining cancer risk
WO2003089897A3 (en) Diagnosis and treatment of vascular disease
CY1106158T1 (en) METHODS FOR ASSESSING CARDIAC STATUS AND COMPOSITIONS FOR THEIR USE
WO2002061131A3 (en) Human single nucleotide polymorphisms
Hayward et al. A novel mutation in the fibrillin gene (FBN1) in familial arachnodactyly
Conrad et al. Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy
KR20170124003A (en) Method for predicting skin pigmentation
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
US6627401B2 (en) Method for detecting a single nucleotide polymorphism in p21waf1/cip1 gene as an indicator of risk of esophageal cancer
WO2000022166A3 (en) Genes for assessing cardiovascular status and compositions for use thereof
WO2000056922A3 (en) Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof
Khurana et al. Update on genetic evidence for rupture-prone compared with rupture-resistant intracranial saccular aneurysms
WO2001018250A3 (en) Single nucleotide polymorphisms in genes
Lühken Genetic testing for phenotype-causing variants in sheep and goats
WO2003054167A3 (en) Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
DE69938837D1 (en) GENOMIC AND COMPLETE CDNA SEQUENCES OF HUMAN ADIPOCYTES SPECIFIC APM1 AND BIALLELIAN MARKERS THEREOF
Yamamoto et al. Primary structure of human amphiphysin, the dominant autoantigen of paraneoplastic Stiff—Man syndrome, and mapping of its gene (AMPH) to chromosome 7p13–p14
WO2004033485A3 (en) Nucleic acid supported protein complementation
ATE246731T1 (en) METHODS AND COMPOSITIONS FOR IDENTIFYING GENETICALLY RESISTANT PIGS TO F18 E. COLI ASSOCIATED DISEASES
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
RU99127287A (en) METHODS AND COMPOSITIONS FOR IDENTIFICATION OF PIGS GENETICALLY RESISTANT TO DISEASES ASSOCIATED WITH F18E. Coli
HUP0302661A2 (en) Genetic test for the identification of carriers of complex vertebral malformations cattle
EP1262565A3 (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
ES2189560A1 (en) Dna polymerase lambda and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC ( EPO-FORM 1205 DATED 25-11-2002)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP